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Abstract Thrombocytopenia (platelet count\150 9 109/L)
often complicates chronic liver disease, impeding optimal
management of these patients. The prevalence of this
manifestation ranges from 6 % among non-cirrhotic
patients with chronic liver disease to 70 % among patients
with liver cirrhosis. It has also been shown that the severity
of liver disease is associated with both prevalence and level
of thrombocytopenia. Its development is often multifacto-
rial, although thrombopoietin is thought to be a major
factor. The discovery of and ability to clone thrombopoi-
etin led to new treatment opportunities for this clinical
manifestation. This review discusses data on the three most
important thrombopoietin receptor agonists: eltrombopag,
avatrombopag, and romiplostim. Currently, only eltrom-
bopag is approved for usage among patients with throm-
bocytopenia and chronic hepatitis C virus infection in order
to initiate and maintain interferon-based antiviral treat-
ment. Nevertheless, the optimal management of hemato-
logic abnormalities among patients with chronic liver
disease, and its risk for bleeding complications, is still a
matter of discussion. Thrombocytopenia definitely con-
tributes to hemostatic defects but is often counterbalanced
by the enhanced presence of procoagulant factors. There-
fore, a thorough assessment of the patient’s risk for
thrombotic events is essential when the use of throm-
bopoietin receptor agonists is considered among patients
with chronic liver disease and thrombocytopenia.
Key Points
Thrombocytopenia in chronic liver disease is often
multifactorial, with severity of liver disease the most
influential factor.
Currently, only eltrombopag has been approved for
use among patients with chronic hepatitis C virus
infection to allow the initiation and maintenance of
interferon-based therapy, but romiplostim and
avatrombopag are also promising agents.
A thorough assessment of the patient’s risk for
thrombotic events is essential when the use of
thrombopoietin receptor agonists is considered
among patients with chronic liver disease and
thrombocytopenia.
1 Introduction
Chronic liver disease is frequently complicated by throm-
bocytopenia (i.e., platelet count \150 9 109/L), which
hampers the medical management of patients [1–5].
Diversity in cut-off values and patient populations means
the prevalence of thrombocytopenia in different studies
ranges from 6 % among non-cirrhotic patients with chronic
liver disease up to 70 % among patients with liver cirrhosis
[6]. Both prevalence and level of thrombocytopenia are
associated with the severity of liver disease, as well as with
long-term outcome of the disease [7–12]. The clinical
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significance of thrombocytopenia has been subject to
intense discussion over recent years. Platelets do indeed
have a critical role in normal hemostasis, hence thrombo-
cytopenia influences coagulopathy in chronic liver disease
[13–15]. However, a normal platelet number of
150–350 9 109/L far exceeds the number of platelets that
is necessary for hemostasis, as major spontaneous bleeding
will generally not occur until the platelet count is
\10 9 109/L [16].
Before the approval of eltrombopag by the US Food and
Drug Administration (FDA) in 2008, and in Europe by the
European Medicines Agency (EMA) in 2009, treatment
options for clinically relevant thrombocytopenia consisted
of platelet transfusion, splenic artery embolization,
splenectomy, and transjugular intrahepatic portosystemic
stent shunting. While these treatment options often effec-
tively increased the platelet count, costs and risks were
substantial. Platelet transfusion, the most effective option,
can become refractory after multiple platelet transfusions
due to human leukocyte antigen alloimmunization. More-
over, it is associated with the development of febrile non-
hemolytic reactions and transfusion-related infections [17–
19]. The other more invasive methods of treating throm-
bocytopenia are also associated with substantial risks [20–
22]. Since 1994, when cloning of thrombopoietin became
possible, several agents have been investigated for the
pharmacological treatment of thrombocytopenia.
The current review focuses on the pathophysiology of
thrombocytopenia, its impact on adequately treating the
underlying disease, and the pharmacological treatment
options for thrombocytopenia that are available or under
investigation.
2 The Life Cycle of Platelets
Platelets are the smallest blood cells, as they consist of
fragments of megakaryocyte cytoplasm. Megakaryocyte
maturation involves nuclear duplication without cell divi-
sion, resulting in very large cells. These megakaryocytes
are located in the bone marrow, next to the sinusoidal
walls, facilitating the exit of large fragments of cytoplasm
into the circulation. Further fragmentation of megakary-
ocyte cytoplasm into individual platelets is the result of
shear forces of the circulating blood [16].
There are several important regulators in the process of
megakaryocytopoiesis, including interleukin (IL)-3, -6, and
-11 and steel factor, among which thrombopoietin is the
dominant hormone (Fig. 1) [23]. The term ‘thrombopoi-
etin’ dates from 1958, when it was first used to describe the
humoral basis of megakaryocyte and platelet production
Fig. 1 The megakaryocytopoiesis process. G-CSF granulocyte-col-
ony stimulating factor. With permission [23]
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[24]. However, the complete process was not understood
until 1994, when cloning this main regulator of platelet
production became possible [25–28]. By then, the cellular
physiology had been understood for a decade. The protein
of thrombopoietin consists of two domains, of which the
amino-terminal shares great homology with erythropoietin
and binds the c-MPL receptor on the surface of
megakaryocytes and platelets. The carboxyl terminal is
responsible for the circulatory half-life of the hormone as
well as for aiding the folding of the polypeptide into the
hormone [23].
Platelets have a lifespan in the circulation of around 10
days [29]. It is estimated that the spleen sequesters
approximately one-third of the circulating platelets. This
fraction increases when splenomegaly is present due to
increased portal venous pressure, but platelet survival time
remains unchanged in this situation [16]. Recently, it was
found that the survival of platelets is regulated by apoptosis
[30]. Mason et al. [30] showed that an intrinsic genetic
program controls platelet survival and thereby dictates their
lifespan. Only a small fraction of platelets is continually
removed from the circulation due to its utilization in
maintaining vascular integrity.
3 Pathogenesis of Thrombocytopenia in Chronic
Liver Disease
The pathogenesis of thrombocytopenia in chronic liver
disease is multifactorial, and different theories have been
proposed. The pathogenesis may depend on the underlying
etiology of the liver disease. The hypothesis of ‘hyper-
splenic thrombocytopenia’ dates from 1966, when Aster
[31] described the pooling of platelets in the spleen in
patients with liver cirrhosis. Cirrhosis is characterized by a
complete distortion of hepatic architecture; it causes loss of
liver cell function and impairment of liver circulation. This
process leads to increased pressure in the portal veins,
splenomegaly, and subsequent thrombocytopenia via the
sequestration of platelets. However, thrombocytopenia may
persist after treatments aimed to reverse portal hyperten-
sion [22, 32]. This suggests that mechanisms other than
‘splenic pooling’ should also be considered. A thorough
evaluation of patients with thrombocytopenia and chronic
liver disease is therefore warranted.
In addition to the sequestration of platelets, the patho-
genesis of thrombocytopenia in chronic liver disease can be
divided into two general points of action. The first is
central and includes myelosuppression caused by the eti-
ological factor or by the treatment thereof. The second is
peripheral, involving autoantibodies against platelets.
The toxic effects of alcohol as well as viral-induced
thrombocytopathy and bone marrow suppression are well
known to cause thrombocytopenia [33, 34]. The exact
mechanisms by which ethanol hampers normal hemato-
poiesis are still unclear. One hypothesis is that the
cytopenia is due to polymorphisms in genes responsible for
metabolism of alcohol-derived reactive aldehydes [35].
Among patients with chronic viral liver disease, the pres-
ence of immune complex-associated platelet clearance and
reticuloendothelial destruction have also been described as
inducing thrombocytopenia. Nagamine et al. [37] showed
that, among 88 % of patients with chronic hepatitis C virus
(HCV) infection, elevated titers of platelet-associated
immunoglobulin G (PAIgG) were present. It is thought that
these immunoglobulins represent immune complex-coated
platelets, and their levels gradually increase as the severity
of liver disease increases. Moreover, the levels of PAIgG
were inversely correlated with platelet count [36, 37].
Treatment-induced thrombocytopenia often compli-
cates interferon-based antiviral treatment for chronic
hepatitis B virus (HBV) or HCV infection [38–40]. Bone
marrow suppression is thought to be the main mechanism
in which interferon causes thrombocytopenia and neutro-
penia [39]. It has also been shown to inhibit progenitor
cells of all hematological lineages. Peck-Radosavljevic
et al. [41] found that, during interferon-based therapy, the
thrombopoietin response is involved in the development
of thrombocytopenia. They assessed thrombopoietin
levels before and after interferon treatment in 30 patients
without cirrhosis and 15 patients with cirrhosis. Median
decrease in platelet count did not differ between these
patients (35 and 32 %, respectively). The increase in
thrombopoietin levels was relatively small for the
decrease in platelet count among the patients without
cirrhosis (median increase 43 %) and even decreased
among cirrhotic patients (median decrease of 5 %). This
blunted thrombopoietin response could contribute to the
occurrence of thrombocytopenia during interferon-based
therapy for chronic HCV infection [41]. Autoantibodies
against platelet surface antigens are frequently found in
patients with chronic liver disease. These autoantibodies
can cause enhanced removal of platelets by the splenic
and hepatic reticuloendothelial system. This leads to rapid
destruction, which is also observed in chronic immune
thrombocytopenic purpura (ITP) [42]. Kajihara et al. [43]
examined anti-platelet autoimmunity in cirrhotic patients
with thrombocytopenia by determining the autoantibody
response to glycoprotein IIb–IIIa (GPIIb–IIIa) in vitro.
This complex is the most important platelet surface
autoantigen recognized by anti-platelet antibodies among
patients with chronic ITP. By stimulating cultures of
peripheral blood mononuclear cells (PBMCs) with
GPIIb–IIIa, the anti-GPIIb–IIIa antibody production was
assessed in 72 patients with liver cirrhosis, 62 patients
with ITP, and 52 healthy controls. The frequency of anti-
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GPIIb–IIIa antibody-producing B cells in patients with
liver cirrhosis was significantly greater than in the healthy
controls (10.9 ± 6.2 vs. 0.4 ± 0.3/105 PBMCs,
p\ 0.001). Even compared with patients with ITP, this
frequency was higher among patients with liver cirrhosis
(8.2 ± 5.2 for ITP patients, p = 0.007). This study sug-
gested that platelet destruction induced by autoantibodies
may partly contribute to the occurrence of thrombocy-
topenia in this specific population [43]. Another inter-
esting study assessed platelet production and destruction
among patients with liver cirrhosis. Of the 91 consecutive
patients with liver cirrhosis included in this study, 36 had
HCV-induced cirrhosis, 40 had alcoholic cirrhosis, and 15
had HBV-induced cirrhosis. Subjects with ITP (25) or
aplastic anemia (10) and healthy blood donors (40) were
included as controls. Patients with liver cirrhosis had
significantly lower levels of thrombopoietin
(29.9 ± 18.1 qg/ml) than did controls (82.3 ± 47.6 qg/
ml) with no difference on the basis of the etiology. In
contrast, thrombopoietin levels were above normal among
patients with ITP (155 ± 76 qg/ml) or aplastic anemia
(508 ± 86.1 qg/ml). Absolute levels of reticulated plate-
lets were lower in patients with liver cirrhosis than in
healthy controls. As a measure of platelet destruction,
plasma glycocalicin was also assessed. The glycocalicin
index was within normal limits among the healthy sub-
jects (0.9 ± 0.2), while significantly higher among
patients with HCV-induced cirrhosis (1.96 ± 1.40),
alcoholic cirrhosis (1.79 ± 1.51), or HBV-induced cir-
rhosis (1.71 ± 1.69) (p\ 0.006 for all). Moreover, serum
anti-platelet antibodies were higher among patients with
HCV-induced liver cirrhosis than among healthy subjects
(p\ 0.006) and those with alcoholic liver cirrhosis
(p\ 0.018) or HBV-induced liver cirrhosis (p\ 0.001).
This study thus showed that patients with liver cirrhosis
have decreased plasma thrombopoietin levels, higher
platelet turnover, and reduced platelet production. More-
over, HCV-induced liver cirrhosis was associated with
higher levels of serum anti-platelet antibodies [44]. Olariu
et al. [45] evaluated several possible causes for throm-
bocytopenia among 81 patients without cirrhosis. They
divided their study population into three groups according
to platelet count and performed a bone marrow biopsy
and assessed anti-platelet antibodies in all patients. They
found that both central and peripheral causes of throm-
bocytopenia were present in patients with a platelet count
\100 9 109/L, whereas the presence of anti-platelet
antibodies alone was more prevalent among patients with
a platelet count between 126 9 109/L and 149 9 109/L
[45]. Although there were some limitations to these
studies, they underline the multifactorial etiology of
thrombocytopenia in chronic liver disease.
4 Impact of Thrombocytopenia on Treating
the Underlying Disease or before Interventions
Thrombocytopenia frequently complicates the manage-
ment of patients with chronic liver disease who require
treatment for their underlying disease or before undergoing
invasive procedures. The two most important clinical sit-
uations in which thrombocytopenia may hamper the man-
agement of these patients are described below.
4.1 Limiting Antiviral Therapy for Chronic HCV
Infection
Chronic HCV infection is a leading cause for end-stage
liver disease and liver transplantation in Europe and the
USA [46]. To prevent progression towards decompensated
liver cirrhosis, patients with HCV are treated with antiviral
treatment aimed at reaching a sustained virological
response (SVR), i.e., absence of HCV RNA in the serum at
6 months after the end of treatment. Indeed, it has been
shown that successful antiviral treatment, leading to SVR,
is associated with a reduced risk of liver failure and liver
transplantation [12, 47]. Until 2013, all treatment regimens
included pegylated interferon alpha (PegIFN). However,
treatment with PegIFN is problematic in patients with liver
cirrhosis, since one of its many side effects is thrombocy-
topenia. Thus, thrombocytopenia is likely to worsen during
antiviral treatment with PegIFN and therefore, severe
thrombocytopenia has generally been regarded as a con-
traindication for PegIFN treatment.
A recent European retrospective multicenter study
including 466 patients with platelets \100 9 109/L
showed that 184 of 466 patients (39.5 %) did not receive
IFN-based therapy during the study period. Treatment was
most frequently withheld due to multiple clinical
characteristics, including hepatic cirrhosis (16.3 %),
thrombocytopenia (16.3 %), and age[60 years (10.9 %).
Overall, thrombocytopenia was reported as the only reason
for withholding treatment in 4.9 % of untreated patients in
this study [3]. These figures are in line with the findings of
Giannini et al. [2], who evaluated 1538 patients with
chronic HCV who were referred between June 2002 and
May 2011 and potentially eligible for antiviral treatment.
They found that thrombocytopenia limited treatment initi-
ation in 6.5 % of patients [2]. A large American study
evaluated potential contraindications for antiviral therapy
in a dataset of 45,690 patients with HCV [48]. Thrombo-
cytopenia was mentioned as a potential contraindication in
1.1 % of the patients, using a lower cut-off (50 9 109/L)
than the two studies mentioned above.
In clinical practice, clinicians have been treating patients
with HCV-induced thrombocytopenia in whom they
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thought the risk of bleeding complications during treatment
would outweigh the risks associated with disease progres-
sion of untreated ongoing HCV infection. To assess the
risks and benefits of PegIFN-based treatment in patients
with HCV with thrombocytopenia, Maan et al. [49] retro-
spectively investigated 546 patients who were consecu-
tively treated in five large hepatology units in Europe and
Canada between 1990 and 2003. Overall, 859 treatments
were administered to 546 patients: in 38 % of the treat-
ments, patients had moderate baseline thrombocytopenia
with platelets between 75 and 150 9 109/L, and in 6 % of
the treatments, patients had severe baseline thrombo-
cytopenia with platelets\75 9 109/L [49]. In this study,
bleeding complications were more common in patients
with platelet counts\50 9 109/L, but were generally mild.
A total of 18 patients with severe thrombocytopenia
reported a bleeding complication: seven had epistaxis, two
had gingival bleeding, six had hematuria, two had rectal
blood loss, and one had a subconjunctival hemorrhage.
Overall, two major bleeding episodes occurred. Both were
variceal bleeding episodes that occurred in patients with
moderate baseline thrombocytopenia, but which were
likely related to the underlying liver disease and portal
hypertension and not directly to the thrombocytopenia.
Although thrombocytopenia was independently associated
with a reduced chance of achieving SVR, once achieved,
SVR was associated with a marked reduction in cirrhosis-
related morbidity and mortality, especially in patients with
baseline thrombocytopenia.
Since the introduction of PegIFN-free direct-acting
antiviral treatment regimens, thrombocytopenia does not
seem to be a contraindication to HCV therapy [50]. In a
recent study including 61 HCV patients who were treated
with a combination of sofosbuvir and ribavirin (RBV)
while on the waiting list for liver transplantation, platelet
counts increased during treatment from a baseline mean of
107 9 109/L to 120 9 109/L at week 24 [51].
4.2 Limiting or Postponing Invasive Procedures
Patients with chronic liver disease often need invasive
procedures for diagnosis or therapy. The presence of
thrombocytopenia can complicate this routine care, leading
to delayed or cancelled invasive procedures. Currently,
there are no globally accepted clinical guidelines for
applying platelet transfusions when these patients undergo
invasive procedures. In general, platelet counts of
C80 9 109/L are often required for physicians in order to
perform a percutaneous liver biopsy. However, some
physicians consider a platelet count C50 9 109/L safe as it
seemed that laparoscopic and transjugular liver biopsies
could be safely performed when platelet count is
[50 9 109/L [52, 53]. A post hoc analysis from the
Hepatitis C Antiviral Long-Term Treatment against Cir-
rhosis (HALT-C) trial assessed 2740 liver biopsies that
were performed in patients with bridging fibrosis and cir-
rhosis due to chronic HCV infection. Only 29 serious
adverse events (1.1 %) were reported, of which bleeding
was the most common (16 cases; 0.6 %). The bleeding rate
was higher among patients with platelet counts\60 9 109/
L [54]. Giannini et al. [55] assessed the incidence of
bleeding following invasive procedures among 121 con-
secutive patients who were being evaluated for liver
transplantation. In total, 50 (49 %) patients underwent
an invasive procedure; 32 (64 %) of them had severe
thrombocytopenia, which, in this study, was defined as a
platelet count \75 9 109/L. Ten (20 %) patients who
underwent an invasive procedure experienced a bleeding
episode, and all had severe thrombocytopenia [55]. Sharma
et al. [56] performed a study among 88 consecutive
patients with end-stage liver disease who needed to
undergo left-sided cardiac catheterization and were
matched to 81 patients without known liver disease. The
procedures were more complicated among the patients with
liver failure, resulting in pseudoaneurysms in 5.7 % (5/88)
of the patients compared with 0 % in the control group
(p = 0.029). Moreover, major bleeding was higher in the
group with liver disease than in the control group (14.8 vs.
3.7 %, p = 0.014), causing a higher need for blood trans-
fusion. Patients with liver failure also had a greater need
for platelet transfusions (48.3 vs. 1.2 %, p\ 0.001).
Thrombocytopenia did not seem to be associated with the
risk for complications, in contrast to pre- and post-proce-
dural international normalized ratio (INR) [56].
A recent retrospective cohort study assessed the bleed-
ing risk and management of bleeding in thrombocytopenic
patients undergoing dental extraction. A total of 68 patients
with hematologic disease and subsequent thrombocyto-
penia (platelet count B100 9 109/L) underwent extraction
of 200 teeth. Five (7.4 %) patients had postoperative
bleeding that could be controlled with routine care and was
more frequent with lower platelet levels (p = 0.048); 32
patients received platelet transfusion and 26 received local
measures, but these interventions had no effect on bleeding
outcomes [57].
5 Therapeutic Options for Thrombocytopenia
in Chronic Liver Disease
Since its cloning, thrombopoietin and its receptor have
been the main focus for the development of pharmaco-
logical treatment options of thrombocytopenia. First-
generation therapeutic thrombopoietin receptor agonists,
among which recombinant human thrombopoietin (rhTPO)
and pegylated human recombinant megakaryocyte growth
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and development factor (Peg-rHuMGDF) have been
demonstrated as highly effective, have never been
approved. The development of these agents ended when
neutralizing autoantibodies were found to form, showing a
cross-reaction with endogenous thrombopoietin, which
sometimes even led to thrombocytopenia in healthy indi-
viduals [58–61]. Because these agents did demonstrate a
clinical benefit, the development of thrombopoietic growth
factors with the potential to stimulate platelet production
but no antigenic effect was warranted. It was not until the
early 2000s that thrombopoietic agents that specifically did
not have any homology to endogenous thrombopoietin
were developed. These agents are c-MPL receptor agonists
and successfully enhance platelet production. Most of these
agents are primarily developed for treating chronic ITP,
and data on their application in thrombocytopenia in
chronic liver disease are limited (Table 1).
5.1 Eltrombopag
Eltrombopag (Revolade; Promacta; GlaxoSmithKline
Inc, Philadelphia, PA, USA) is an orally available, non-
peptide acting as a thrombopoietin receptor agonist. The
drug interacts with the transmembrane domain of the
thrombopoietin receptor on megakaryocyte precursors and
megakaryocytes and induces their proliferation and dif-
ferentiation in order to increase platelet production. After
the preclinical and early clinical studies, eltrombopag was
subject to one phase II trial and three phase III trials, which
are described below. Three of these trials only included
patients with chronic HCV infection, whereas the other
trial included patients with cirrhosis of any origin.
Recently, this journal published an excellent and detailed
review on eltrombopag [62].
The first phase II trial dates from 2007, when
McHutchison et al. [63] assessed whether the use of
eltrombopag could increase platelet counts in patients with
thrombocytopenia associated with cirrhosis due to chronic
HCV infection in order to be able to initiate and maintain
antiviral treatment with PegIFN and RBV. In total, 74
patients with HCV-related cirrhosis and a platelet count of
20–70 9 109/L were included and were treated for
4 weeks with placebo or eltrombopag (30, 50, or 75 mg
daily). During the 4-week initiation phase, platelet counts
increased in a dose-dependent manner (p\ 0.001 for
overall treatment effect). Antiviral treatment could be ini-
tiated in 71–91 % of patients who were treated with
eltrombopag, and the use of eltrombopag was continued
during this treatment phase. In total, 36–65 % of the
patients completed 12 weeks of antiviral treatment, with
65 % of those receiving eltrombopag 75 mg. The most
common side effects reported in this trial were headache,
dry mouth, abdominal pain, and nausea. Furthermore,
seven serious adverse events occurred, including ascites,
retinal exudates, and myositis [63]. Due to these promising
results, three phase III trials were conducted. The Eltrom-
bopag Evaluated for Its Ability to Overcome Thrombocy-
topenia and Enable Procedures (ELEVATE) study
randomly assigned 292 patients with chronic liver disease
of diverse causes, all of whom had a platelet count of
\50 9 109/L. Patients received a daily dose of eltrom-
bopag 75 mg or placebo for 14 days before an elective
invasive procedure, which was performed within 5 days of
the last dose. A platelet transfusion was avoided in 104
(72 %) of the 145 patients who received eltrombopag,
whereas transfusion was avoided in 28 (19 %) of 147
patients receiving placebo (p\ 0.001). There were no
significant differences in bleeding episodes. The most
common side effects reported in this study (in [5 % of
patients) were headache, pyrexia, abdominal pain, diarrhea,
nausea, and hepatic encephalopathy. A thrombotic event of
the portal venous system was observed in six patients
receiving eltrombopag and one patient receiving placebo.
Five of the six patients had their event while the platelet
count was C200 9 109/L. This resulted in early termina-
tion of the study [64].
Two pivotal, multicenter, randomized phase III trials,
Eltrombopag to Initiate and Maintain Interferon Antiviral
Treatment to Benefit Subjects with Hepatitic C-Related
Liver Disease (ENABLE)-1 and ENABLE-2, assessed the
ability of eltrombopag to increase the platelet count and
thereby enable subjects to initiate and maintain antiviral
treatment with PegIFN and RBV. Both trials had an initi-
ation phase using eltrombopag to increase platelet count
above the threshold for treatment initiation (ENABLE-1:
90 9 109/L, using PegIFN-2a; and ENABLE-2:
100 9 109/L, using PegIFN-2b). Afterwards, patients were
randomized to eltrombopag or placebo for the whole
course of antiviral treatment. These trials included patients
with chronic HCV infection and a platelet count
\75 9 109/L; ENABLE-1 included 715 patients and
ENABLE-2 included 805 patients. The threshold for
treatment initiation was reached in 95 % and 94 % of
patients in ENABLE-1 and 2, respectively. In both trials,
more patients who received eltrombopag than placebo
achieved SVR. In ENABLE-1, 23 % of patients treated
with eltrombopag attained SVR versus 14 % in the placebo
group (p = 0.0064), and 19 % of patients treated with
eltrombopag versus 13 % among those treated with pla-
cebo attained SVR in ENABLE-2 (p = 0.0202). Regarding
side effects, the safety of eltrombopag remained an
important issue, as the rates of hepatic decompensation
(10 % with eltrombopag vs. 5 % with placebo) and
thromboembolic events (3 % with eltrombopag and 1 %
with placebo) were higher in the group receiving eltrom-
bopag [65]. Participants are currently being recruited for
1986 R. Maan et al.
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enrolment in SQUELCH-C, an investigator-initiated, sin-
gle-arm, non-blinded pilot study on the use of eltrombopag
in combination with PegIFN, RBV and boceprevir, for
patients who would not otherwise be treatment candidates
because of low platelet counts (\75 9 109/L) (Clinical
trial no: NCT01821625).
5.2 Avatrombopag
Avatrombopag (E5501, formerly YM477 and AKR-501;
Eisai Inc, Woodcliff Lake, NJ, USA) is an orally admin-
istered, small-molecule thrombopoietin receptor agonist
that has been shown to act like thrombopoietin in vitro and
in vivo [66, 67]. Like eltrombopag, it binds the throm-
bopoietin receptor and induces a cascade of cellular reac-
tions that eventually leads to enhancement of
megakaryocytic proliferation and differentiation and
thereby the production of platelets. To date, one phase II
multicentre study has been published, in which the efficacy
and safety of avatrombopag was assessed among patients
with cirrhosis and thrombocytopenia (10–58 9 109/L) who
had to undergo elective procedures. This study included
130 patients who were randomized to cohort A (67
patients) or cohort B (63 patients). In cohort A, patients
were treated with placebo or three different doses of a first-
generation avatrombopag formulation (100 mg loading
dose followed by 20, 40, or 80 mg/day on days 2–7).
Patients in cohort B were treated with placebo or a second-
generation avatrombopag formulation (80 mg loading
dose, followed by 10 mg/day for days 2–7, or 20 mg/day
for days 2–4). Phase I studies showed that the second-
generation formulation produced about 1.6 times the
exposure compared with the first-generation formulation
[66, 67]. In the treated group, 49 % of patients in cohort A
(vs. 6 % among controls, p\ 0.001) achieved an increase
in platelet count of at least C20 9 109/L compared with
baseline and a platelet count of[50 9 109/L at least once
during days 4–8. In cohort B, 48 % of the treated patients
achieved this primary endpoint compared with 10 % of
patients receiving placebo (p = 0.009). Platelet count
increased in a dose-dependent manner among the patients
treated with avatrombopag. As data were emerging
regarding the association between these agents and portal
vein thrombosis (PVT), a baseline Doppler ultrasound was
included before cohort B was enrolled. In general, ava-
trombopag was well tolerated; nausea, fatigue, and head-
ache were most commonly reported. Two patients achieved
a platelet count[200 9 109/L and neither of them devel-
oped a PVT. Only one patient, who was treated in cohort A
with 100/80 mg, developed a PVT in this study. The patient
had a Child-Turcotte-Pugh score of 10 (CTP C) and a
model for end-stage liver disease (MELD) score of 19,
indicating severe liver disease. Moreover, a prior
ultrasound demonstrated low portal vein flow (*5 cm/s),
probably increasing the risk of developing a PVT [68].
Currently, two global phase III trials are ongoing evaluat-
ing the efficacy and safety of once-daily oral avatrombopag
for the treatment of adults with thrombocytopenia associ-
ated with liver disease prior to an elective procedure
(Clinical trial no: NCT01972529 and NCT01976104).
Furthermore, data are awaited from a phase II study eval-
uating the efficacy, safety, and pharmacokinetics of E5501
in subjects with chronic HCV-related thrombocytopenia
who are potential candidates for antiviral treatment (Clin-
ical trial no: NCT01355289).
5.3 Romiplostim
Romiplostim (NplateTM; Amgen Inc., Thousand Oaks, CA,
USA) is another thrombopoietin receptor agonist that has
four identical thrombopoietin agonist peptides and glycine
bridges to connect these peptides. It also contains an Fc
carrier domain to increase its half-life. The peptide has no
sequence homology to endogenous thrombopoietin to avoid
cross-reactive antibodies. Its mechanism of action is thought
to be similar to that of thrombopoietin, directly binding to the
thrombopoietin receptor and thereby initiating the signaling
pathways. Recently, a single-center, single-arm, open-label
study was conducted investigating the effect of preoperative
romiplostim treatment among 35 Egyptian patients with
chronic HCV infection, liver cirrhosis (CTP C), and subse-
quent thrombocytopenia (B50 9 109/L). Patients had not
responded to standard treatment and were treated with a
weekly subcutaneous injection at a fixed dose of 2 lg/kg.
They were treated for a maximum of 4 weeks or until two
consecutive visits with a platelet count of C70 9 109/L. In
total, 33 (94 %) of the 35 patients achieved the primary
endpoint of two consecutive visits with a platelet count
C70 9 109/L. Most of the patients reached this target
between day 12 and day 18. The two patients who did not
reach this level achieved platelet counts of 48 and
61 9 109/L. Surprisingly, no serious adverse events were
observed during the treatment period. None of the subjects
experienced a postoperative bleeding episode, and none of
them experienced a thromboembolic event 60 days after the
procedure. Some patients experienced some degree of
headache on the day of the injection, but no other side effects
were reported [69]. A phase II trial assessing the efficacy and
safety of romiplostim administered to thrombocytopenic
patients with chronic HCV infection who are not candidates
for antiviral treatment with PegIFN and RBV due to persis-
tent thrombocytopenia has currently suspended participant
recruitment and an interim analysis is awaited (Clinical trial
no:NCT01153919). So far, three case reports describing four
patients with chronic HCV infection (one had HIV/HCV co-
infection) have shown that romiplostimwas able to initiate or
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maintain antiviral therapy with PegIFN and RBV and
thereby these patients were able to achieve an SVR [70–72].
Another case report described a patient with HCV-induced
cirrhosis who had to undergo treatment for a hepatoma.
Treatment was withheld because of thrombocytopenia, and
after starting romiplostim the patient was successfully trea-
ted [73]. A final case report again stresses the importance of
appropriate patient selection and close monitoring while
patients are receiving thrombopoietin receptor agonists.
Dultz et al. [74] described a cirrhotic patient with chronic
HCV infection who was treated for thrombocytopenia with
romiplostim for 9 months. Shewas found to have a PVT, and
the platelet count was[330 9 109/L.
6 Conclusion
Thrombocytopenia is a common manifestation among
patients with chronic liver disease and could be considered
as an important parameter for defining the severity of the
liver disease. The pathogenesis of thrombocytopenia is
often multifactorial, with thrombopoietin being essential in
the current development of pharmacotherapeutic agents. So
far, only eltrombopag has been approved for usage among
patients with chronic HCV infection to allow the initiation
and maintenance of IFN-based therapy [75, 76]. Romi-
plostim has been approved for the treatment of thrombo-
cytopenia in patients with chronic ITP who have insufficient
response to corticosteroids, immunoglobulins, or splenec-
tomy. However, its usage is not approved in chronic liver
disease [77, 78]. Avatrombopag is a promising agent that
could probably be used for thrombocytopenic patients with
chronic liver disease undergoing elective procedures. As
data comparing one thrombopoietin agonist with another
are lacking, it is hard to recommend its usage in the man-
agement of thrombocytopenia among patients with chronic
liver disease. The use of eltrombopag (and romiplostim
when approved in chronic liver disease) should be limited to
those patients who require chronic thrombopoietin stimu-
lation, like patients undergoing PegIFN-based antiviral
therapy for chronic HCV infection. However, its use among
these patients is a major concern. The risk of hepatic
decompensation is considerably increased when patients
with severe thrombocytopenia are allowed to undergo
PegIFN-based antiviral treatment. Recently, the discovery
of direct-acting antivirals has revolutionized treatment for
patients with chronic HCV infection. It could therefore be
questioned whether patients with chronic HCV infection
and thrombocytopenia still necessitate thrombopoietin
receptor agonists, as most regimens have abandoned the
usage of PegIFN or shortened its usage to 12 weeks
[79–81]. When a temporary increase in platelet count is
needed, avatrombopag should be considered, since most
data on the use of avatrombopag are among patients with
liver cirrhosis undergoing elective procedures. Whether
there is an optimal platelet count that should be attained
after initiation of a thrombopoietin agonist is currently
unclear, but it very much depends on the indication for its
use. Before considering prescribing a thrombopoietin ago-
nist, physicians must perform extensive evaluation of a
patient’s risk of thrombotic events. This evaluation includes
the assessment of the presence of patent hepatic vessels and
flow in the portal vein. Once thrombopoietin agonists are
being used, patients should be closely monitored by Dop-
pler sonography as well as for abdominal complaints. As
one of the studies on eltrombopag suggested an association
between platelet count[200 9 109/L and the occurrence of
PVT events, termination of thrombopoietin agonists should
be considered when this threshold has been exceeded [64].
The optimal management of hematologic abnormalities
among patients with chronic liver disease and its risk for
bleeding complications is still a matter of discussion. The
balance in the hemostatic system among patients with
chronic liver disease, including coagulation, platelets, and
fibrinolysis, has been extensively described elsewhere [14].
Thrombocytopenia definitely contributes to hemostatic
defects but is often counterbalanced by the enhanced
presence of procoagulant factors. Therefore, a thorough
assessment of the patient’s risk for thrombotic events is
essential when the use of thrombopoietin receptor agonists
is considered among patients with chronic liver disease and
thrombocytopenia.
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